Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer.
Mariano Provencio PullaDiego Pérez-ParenteSara OlsonHaroon HasanBegoña Campos BaleaDelvys Rodriguez AbreuMarta López-Brea PiquerasNavdeep PalSamantha V WilkinsonEsther VilasPedro Ruiz-GraciaManuel CoboPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)
Our results provide evidence on the prognostic value of STK11, KEAP1, and CDKN2A/B mutations in patients with aNSCLC. Further research is required to better understand the implications of these findings on patient management and future trial design and treatment selection.